Travere Therapeutics Inc (TVTX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $4.86B
Last updated: Nov 17, 2026 at 4:15 PM ET
Travere Therapeutics Inc (TVTX) Stock Chart
Travere Therapeutics (TVTX) has a latest price of $51.10 on Nov 17, 2026, 25.7% below its 52-week high of $68.73. Its price rose 48.1% over the past 12 months. The month-end price rose 167.3% over the 10 years through Oct 2026, a compound annual rate of 10.3%.
Price Chart
From Oct 2016 to Oct 2026, its highest month-end close was $66.28 in Aug 2026 and its lowest $5.53 in Apr 2024, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart TVTX with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for TVTX.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price fell 22.5%, and over 6 months it rose 20.9%. The month-end price rose 677.6% over the 3 years through Oct 2026, a compound annual rate of 98.1%.
| Period | Change |
|---|---|
| 1 month | +1.2% |
| 3 months | -22.5% |
| 6 months | +20.9% |
| 12 months | +48.1% |
| 12 months, with dividends | +48.1% |
| Period | Change | Per year |
|---|---|---|
| 3 years | +677.6% | +98.1% |
| 5 years | +74.9% | +11.8% |
| 10 years | +167.3% | +10.3% |
Price by Year
Its best calendar year was 2025, when the price rose 119.3%, and its weakest was 2023, when it fell 57.3%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $50.39 | +31.9% |
| 2025 | $38.21 | +119.3% |
| 2024 | $17.42 | +93.8% |
| 2023 | $8.99 | -57.3% |
| 2022 | $21.03 | -32.2% |
| 2021 | $31.04 | +13.9% |
| 2020 | $27.25 | +91.9% |
| 2019 | $14.20 | -37.3% |
| 2018 | $22.63 | +7.4% |
| 2017 | $21.07 | +11.3% |
Trading Range
The price is 7.6% below its 50-day average of $55.32 and 6.8% above its 200-day average of $47.87.
| Measure | Value | Price vs |
|---|---|---|
| Latest price (Nov 17, 2026) | $51.10 | |
| 52-week high | $68.73 | -25.7% |
| 52-week low | $22.59 | +126.2% |
| 50-day average | $55.32 | -7.6% |
| 200-day average | $47.87 | +6.8% |
Price Risk
Over 3 years, its largest fall from a peak was 46.4%.
| Measure | Value |
|---|---|
| 1-year beta | 1.26 |
| Largest fall, 1 year | -33.5% |
| Largest fall, 3 years | -46.4% |
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About TVTX
What is TVTX's 1-year price change?
Travere Therapeutics's price rose 48.1% over the past 12 months. With dividends included, the 12-month total return was 48.1%.
What is TVTX's 5-year price change?
Travere Therapeutics's month-end price rose 74.9% over the 5 years through Oct 2026, a compound annual rate of 11.8%. These figures leave out dividends.
What is TVTX's 52-week high and low?
Travere Therapeutics's 52-week high is $68.73 and its 52-week low is $22.59. Its latest price of $51.10 on Nov 17, 2026 is 25.7% below the high.
What is TVTX's beta?
Travere Therapeutics's 1-year beta against the S&P 500 is 1.26, so its price has moved more than the market over the past year. Its largest fall from a peak over the past year was 33.5%.
Is the TVTX chart free?
Yes. Advanced Charting for TVTX is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
TVTX pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors, Government Contracts